Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Korean patients with type 2 diabetes mellitus: a 24-week multicentre, randomized, double-blind, placebo-controlled phase III trialopen access
- Authors
- Hong, S.; Park, C. -Y.; Han, K. A.; Chung, C. H.; Ku, B. J.; Jang, H. C.; Ahn, C. W.; Lee, M. -K.; Moon, M. K.; Son, H. S.; Lee, C. B.; Cho, Y. -W.; Park, S. -W.
- Issue Date
- May-2016
- Publisher
- WILEY
- Keywords
- antidiabetic drug; DPP-IV inhibitor; phase III study; type 2 diabetes
- Citation
- DIABETES OBESITY & METABOLISM, v.18, no.5, pp.528 - 532
- Indexed
- SCIE
SCOPUS
- Journal Title
- DIABETES OBESITY & METABOLISM
- Volume
- 18
- Number
- 5
- Start Page
- 528
- End Page
- 532
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/5050
- DOI
- 10.1111/dom.12631
- ISSN
- 1462-8902
- Abstract
- We assessed the 24-week efficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Korean patients with type 2 diabetes mellitus (T2DM) that was inadequately controlled with diet and exercise. The present study was designed as a multicentre, randomized, double-blind, placebo-controlled, parallel-group, phase III study. Patients (n = 142) were randomized 2 : 1 into two different treatment groups as follows: 99 received teneligliptin (20 mg) and 43 received placebo. The primary endpoint was change in glycated haemoglobin (HbA1c) level from baseline to week 24. Teneligliptin significantly reduced the HbA1c level from baseline compared with placebo after 24weeks. At week 24, the differences between changes in HbA1c and fasting plasma glucose (FBG) in the teneligliptin and placebo groups were -0.94% [least-squares (LS) mean -1.22, -0.65] and -1.21 mmol/l (-1.72, -0.70), respectively (all p < 0.001). The incidence of hypoglycaemia and adverse events were not significantly different between the two groups. This phase III, randomized, placebo-controlled study provides evidence of the safety and efficacy of 24weeks of treatment with teneligliptin as a monotherapy in Korean patients with T2DM.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 서울 의과대학 > 서울 내과학교실 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/5050)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.